What I think is important to keep in mind is that
Post# of 148168
I think what matters for purposes of our investment is whether or not the patients they receive leronlimab in the clinical trials improve and/or survive at a statistically significant higher rate than their placebo counterparts.
If that happens, our investment will be in good shape in the short term (I have no doubt it will be in good shape in the long term).